Aravive is currently conducting clinical trials of its lead compound, AVB-500, in combination with standard anticancer treatments in multiple indications. For information on our AXLerate Phase 3 trial in platinum-resistant ovarian cancer, please visit www.clinicaltrials.gov or https://ovariancancertrial.com/en-us. For information on our Phase 1b/2 trial in renal cell carcinoma, please visit the study page at www.clinicaltrials.gov. For information on our Phase 1b/2 trial in pancreatic adenocarcinoma, please visit the study page at www.clinicaltrials.gov.
Platinum-Resistant Ovarian Cancer
Our first indication is recurrent platinum-resistant ovarian cancer. Ovarian cancer is relatively uncommon, representing an estimated 1.3 percent of new cancer cases diagnosed each year. Unfortunately, most patients with ovarian cancer are diagnosed with advanced-stage disease, when metastasis has already occurred.
Although clinical complete remissions are often achieved through a combination of surgery and chemotherapy, relapse and drug resistance are common. Thus, there is considerable need for new therapies for the treatment of ovarian cancer in this relapsed, second-line setting.
Clear Cell Renal Cell Carcinoma
Kidney cancer is a leading cause of cancer-related deaths in the United States and is among the 10 most common cancers in both men and women. Clear cell renal cell carcinoma is a cancer of the kidney and accounts for more than 75% of malignant kidney tumors. Metastasis to distant organs including the lung, bone, liver and brain is the primary cause of death in kidney cancer patients, and only 12% of people with metastatic kidney cancer will survive past 5 years.
Pancreatic cancer is the seventh leading cause of cancer death worldwide. Pancreatic cancer typically has a poor prognosis, and the five-year survival rate is approximately 11%. Pancreatic adenocarcinoma is the most common type of pancreatic cancer, and there is a clear, high, unmet medical need to improve patient survival with new effective treatments that are safe and well-tolerated. Pancreatic cancer is projected to become the third leading cause of cancer death worldwide by 2025 and the second leading cause of cancer death in the U.S.